This award-winning (2016 AACC Coulter Award, McDevitt lab) programmable platform has been adapted recently for oncology screening applications. Through these efforts, OraLiva is positioned to be the first company to provide a powerful programmable cytology diagnostic platform for various oncological indications suitable for use at the point of care. These highly-scalable diagnostic tools have potential to deliver new test and treat capabilities that can help to usher in arrival of precision oncology diagnostic care. The cornerstone of this transformative platform is OraLiva’s proprietary "C-AIIDE" (Cytology Artificial Intelligence IDEntification) technology that allows for multiparameter single-cell cytology measurements to be completed in near real-time. These integrated diagnostic tools include a "lab in a kit" that the physician uses to collect patient sample, and a proprietary, multi-layered machine learning algorithm that conducts analysis and provides an assessment of patient's status. The lab in a kit and algorithm are designed to augment and improve upon current diagnostic capabilities including flow cytometry, tissue biopsy/histology and lab-based manual cytology tests which are less accurate and more costly to run per test.


Health Care

Health Diagnostics

Life Sciences

Medical Devices

Oraliva, Inc.

Oraliva, Inc.'s headquarters in New York, United States

Description

People (3)

Nick Christodoulides

Michael P. McRae

Todd Haran

Jobs